Trials of Mefloquine in Vivax and of Mefloquine Plus 'Fansidar' in Falciparum Malaria

Harinasuta, T; R, Lasserre; Bunnag, D; Leimer, R.; Vinijanont, S.

doi:10.1016/s0140-6736(85)91670-8

Cited by 68 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recrudescence of falciparum malaria has been documented in patients with plasma mefloquine concentrations between 228 and 776 ng ml-' 7 days after starting treatment (Harinasuta et al, 1985). Estimates of minimum therapeutic concentration based on in vitro testing could be particularly unreliable for mefloquine because of its tendency to bind to cell membranes, proteins and plastic.…”

Section: Discussionmentioning

confidence: 99%

Plasma and whole blood mefloquine concentrations during treatment of chloroquine‐resistant falciparum malaria with the combination mefloquine‐sulphadoxine‐pyrimethamine.

Karbwang

Phillips

Wattanagoon

et al. 1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

Mefloquine-sulphadoxine-pyrimethamine (MSP) in combination has proved effective against multiple-drug-resistant falciparum malaria, but nothing is known about mefloquine absorption when it is given in this formulation. Nine Thai patients, aged 15-51 years with uncomplicated chloroquine-resistant falciparum malaria, took 11.2-16.7 mg of mefloquine base per kilogram bodyweight as MSP tablets. All patients responded to treatment with fever and parasite clearance times of 61 ± 29 h (mean ± s.d.) and 52 ± 24 h, respectively.The mean apparent absorption half-time (t½/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-' (range 725-3368). Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1. There was no significant difference between plasma and whole blood mefloquine concentrations during the first 48 h of treatment. Based on the elimination of parasitaemia, the plasma mefloquine concentrations are adequate for therapy of uncomplicated falciparum malaria although the relationship between plasma concentrations and therapeutic efficacy of mefloquine requires further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma and whole blood mefloquine concentrations during treatment of chloroquine‐resistant falciparum malaria with the combination mefloquine‐sulphadoxine‐pyrimethamine.

Karbwang

Phillips

Wattanagoon

et al. 1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Effective therapies for chloroquine-resistant P. vivax A few reports describe the efficacy of approved drugs for the treatment of P. vivax [50][51][52][53], and some reports describe treatments for CQ-resistant P. vivax [54][55][56]. Mefloquine (MQ) combined with PQ was effective in Papua, Indonesia (98% efficacy) [47], and CQ combined with PQ was much more effective than CQ alone [47,54].…”

Section: Failing Chloroquine Therapymentioning

confidence: 99%

Neglect of Plasmodium vivax malaria

Baird¹

2007

Trends in Parasitology

240

166

View full text Add to dashboard Cite

“…No clinical data yet support that recommendation. Mefloquine proved effective against CQ-resistant P. falciparum and was effective against CQ-sensitive P. vivax (3,43,62). Good efficacy against CRPV seems a reasonable supposition, and Collins et al (37) demonstrated that mefloquine had good efficacy against an Indonesian CRPV strain in Aotus monkeys.…”

Section: Alternative Therapiesmentioning

confidence: 99%